Mana.bio
Tel Aviv company using machine learning with high-throughput screening and nanotechnology to discover and optimise customisable lipid nanoparticles for tissue-specific delivery of RNA and DNA therapeutics and vaccines; it also offers Mina (ChatLNP), an AI agent for lipid-nanoparticle design.
Headquarters
Tel Aviv, Israel
Year Founded
2021
Founders
Yogev Debbi (CEO), Roy Nevo (CTO), Avi Schroeder, Kira Radinsky
Country
Israel
Financial Information
Funding Stage
Seed
Recent Funding
$19.5M
Funding By
Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, Technion
Core Technology
ML-optimised lipid nanoparticle design with high-throughput screening
Product Type
Drug Delivery Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Not disclosed
Academic / Hospital Tie-ups
Technion - Israel Institute of Technology (scientific founding)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Customisable LNP design for tissue-specific delivery, plus an AI agent for formulation work